Alluvi, formerly BI 4744, represents a notable advance in obesity treatment. This dual agonist targeting both GLP-1 and GIP targets demonstrates impressive effectiveness in clinical studies, arguably outperforming https://alluvi891653.alltdesign.com/alluvi-a-detailed-examination-into-the-medication-s-potential-62094327